# A Multi-center, Randomized, Double-blind Phase III Clinical Trial to Assess and Compare to the Efficacy and Safety of Lafutidine, Famotidine and Omeprazole-referenced in Korean Erosive Esophagitis Patients

> **NCT01499368** · PHASE3 · COMPLETED · sponsor: **Boryung Pharmaceutical Co., Ltd** · enrollment: 495 (actual)

## Conditions studied

- Erosive Esophagitis

## Interventions

- **DRUG:** Lafutidine
- **DRUG:** Famotidine
- **DRUG:** Omeprazole

## Key facts

- **NCT ID:** NCT01499368
- **Lead sponsor:** Boryung Pharmaceutical Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-11
- **Primary completion:** 2012-11
- **Final completion:** 2012-11
- **Target enrollment:** 495 (ACTUAL)
- **Last updated:** 2025-01-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01499368

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01499368, "A Multi-center, Randomized, Double-blind Phase III Clinical Trial to Assess and Compare to the Efficacy and Safety of Lafutidine, Famotidine and Omeprazole-referenced in Korean Erosive Esophagitis Patients". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01499368. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*